{"disease":{"id":"relapsed-or-refractory-b-cell-non-hodgkin-lymphoma","name":"relapsed or refractory b cell non hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07439653","title":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":155,"lead_sponsor_name":"TORL Biotherapeutics, LLC","has_results":false},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06189391","title":"A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"MSD R&D (China) Co., Ltd.","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06565689","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Excyte Biopharma Ltd","has_results":false},{"nct_id":"NCT06970496","title":"A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03263637","title":"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05370430","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"PeproMene Bio, Inc.","has_results":false},{"nct_id":"NCT05008055","title":"Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07345741","title":"Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT05020015","title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05784441","title":"A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05797948","title":"GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03456726","title":"Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT05105867","title":"CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","has_results":false},{"nct_id":"NCT03985189","title":"Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false},{"nct_id":"NCT03664635","title":"MB-CART20.1 Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Miltenyi Biomedicine GmbH","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT03009344","title":"A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":true},{"nct_id":"NCT05619367","title":"A Compassionate Use (CU) Program of Odronextamab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}